000 01445 a2200373 4500
005 20250518040425.0
264 0 _c20191211
008 201912s 0 0 eng d
022 _a1873-264X
024 7 _a10.1016/j.jpba.2019.04.035
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aScherf-Clavel, Oliver
245 0 0 _aThe contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.
_h[electronic resource]
260 _bJournal of pharmaceutical and biomedical analysis
_cAug 2019
300 _a278-284 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAmides
_xchemistry
650 0 4 _aAngiotensin II Type 1 Receptor Blockers
650 0 4 _aChromatography, High Pressure Liquid
_xmethods
650 0 4 _aDrug Contamination
_xprevention & control
650 0 4 _aNitrosamines
_xchemistry
650 0 4 _aTandem Mass Spectrometry
_xmethods
650 0 4 _aValsartan
_xchemistry
700 1 _aKinzig, Martina
700 1 _aBesa, Axel
700 1 _aSchreiber, André
700 1 _aBidmon, Clemens
700 1 _aAbdel-Tawab, Mona
700 1 _aWohlfart, Jonas
700 1 _aSörgel, Fritz
700 1 _aHolzgrabe, Ulrike
773 0 _tJournal of pharmaceutical and biomedical analysis
_gvol. 172
_gp. 278-284
856 4 0 _uhttps://doi.org/10.1016/j.jpba.2019.04.035
_zAvailable from publisher's website
999 _c29679899
_d29679899